Serum Interleukin-6 and Adiponectin Levels in Patients with Active or Inactive Behcet's Disease

dc.contributor.authorEtem, Arzu
dc.contributor.authorYildirmak, Sembol Turkmen
dc.contributor.authorOnalan, Ebru Etem
dc.contributor.authorBaran, Fehmi
dc.contributor.authorSeval, Hatice
dc.contributor.authorKoldas, Macir
dc.contributor.authorYenice, Necati
dc.date.accessioned2026-08-12T16:35:32Z
dc.date.issued2010
dc.departmentFırat Üniversitesi
dc.description.abstractObjective: Behcet's disease (BD) is a chronic systemic inflammatory disease and its etiopathogenesis still remains unknown. Cytokines play a role in immune response and inflammatory reactions. The aim of this study is to determine the levels of proinflammatory cytokine interleukin-6 (IL-6) and anti-inflammatory cytokine adiponectin in the sera of patients with BD and to assess their importance as biological markers for disease activity. Material and Methods: Forty-four BD patients [19 males, 25 females, age: 35.65 +/- 10.84 yrs (mean +/- standart deviation) (SD)] and 25 healthy controls (10 males, 15 females, age: 29.80 +/- 8.20 yrs) were included in the study. Patients were divided into active or inactive groups according to their clinical and laboratory findings (active, n= 21; inactive, n= 23). We determined serum IL-6 levels using the chemiluminescence method, and serum adiponectin levels by ELISA method. Results were expressed as mean +/- standard error (SE). Results: Serum levels of IL-6 and adiponectin in BD patients (n= 44) (5.24 +/- 0.84 pg/mL; 22.31 +/- 1.71 mu g/mL, respectively) were similar to the control group (n= 25) (4.59 +/- 1.01 pg/mL; 21.68 +/- 1.91 mu/mL, respectively). No significant difference was found in IL-6 and adiponectin levels between the active (n= 21), inactive (n= 23) and control (n= 25) groups. Conclusion: In parallel with the presence of inflammation and increased CRP, erythrocyte sedimentation rate and white blood cell count, higher IL-6 and lower adiponectin levels were expected in active BD patients compared to the controls. However, they were found to be similar in all groups. We conclude that ongoing anti-inflammatory treatment should be taken into consideration while interpreting the cytokine levels in these patients.
dc.identifier.doi10.5336/medsci.2009-15065
dc.identifier.endpage1844
dc.identifier.issn1300-0292
dc.identifier.issn2146-9040
dc.identifier.issue6
dc.identifier.orcid0000-0002-7031-6516
dc.identifier.scopus2-s2.0-78650960887
dc.identifier.scopusqualityQ4
dc.identifier.startpage1837
dc.identifier.urihttps://doi.org/10.5336/medsci.2009-15065
dc.identifier.urihttps://hdl.handle.net/11508/44935
dc.identifier.volume30
dc.identifier.wosWOS:000287053500008
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherOrtadogu Ad Pres & Publ Co
dc.relation.ispartofTurkiye Klinikleri Tip Bilimleri Dergisi
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260511
dc.subjectBehcet's syndrome
dc.subjectadipokines
dc.subjectinterleukin-6
dc.titleSerum Interleukin-6 and Adiponectin Levels in Patients with Active or Inactive Behcet's Disease
dc.title.alternativeAktif ya da inaktif behçet hastali?i bulunan hastalarin serum interlökin-6 ve adiponektin seviyeleri
dc.typeArticle

Dosyalar